Open AccessPrenatal Exposure to Serotonin Reuptake Inhibitors and Congenital Heart Anomalies: An Exploratory Pharmacogenetics Study
Author(s) -
Nur Aizati Athirah Daud,
Jorieke E. H. Bergman,
Wilhelmina S. KerstjensFrederikse,
Pieter van der Vlies,
Eelko Hak,
Rolf M.F. Berger,
Henk Groen,
Bob Wilffert
Publication year - 2017
Publication title -
pharmacogenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.541
H-Index - 91
eISSN - 1744-8042
pISSN - 1462-2416
DOI - 10.2217/pgs-2017-0036
Subject(s) - cyp2c19 , cyp2d6 , pharmacogenetics , medicine , cyp2c9 , pharmacology , bioinformatics , psychiatry , genotype , genetics , biology , gene , cytochrome p450 , metabolism
To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom